

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 October 2024 (10.10.2024)



(10) International Publication Number
WO 2024/211712 A9

(51) International Patent Classification:

C07D 498/22 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2024/023272

(22) International Filing Date:

05 April 2024 (05.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/457,850 07 April 2023 (07.04.2023) US
63/611,585 18 December 2023 (18.12.2023) US
63/624,178 23 January 2024 (23.01.2024) US

(71) Applicant: **REVOLUTION MEDICINES, INC.**
[US/US]; 700 Saginaw Drive, Redwood City, CA 94063 (US).

(72) Inventors: **KOLTUN, Elena, S.**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **KNOX, John, E.**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **LUU, Nguyen, Hong Quang**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **PARSONS, Dylan, E.**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **THOMPSON, Severin**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **TOMLINSON, Aidan**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **TYE, Mark**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **WU,**


Kingsley, Y.; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **BUCKL, Andreas**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **BURNETT, G., Leslie**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **CREGG, James**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **EDWARDS, Anne, V.**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **GILL, Adrian, L.**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US).

(74) Agent: **BELLIVEAU, Michael, J.** et al.; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 02110 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: MACROCYCLIC RAS INHIBITORS



(57) Abstract: The disclosure features macrocyclic compounds of formula (Ia) or (Ib), and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

[Continued on next page]

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(88) Date of publication of the revised international search report:

20 February 2025 (20.02.2025)

(15) Information about Correction:

see Notice of 20 February 2025 (20.02.2025)

Previous Correction:

see Notice of 21 November 2024 (21.11.2024)